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Secreted chemokines are critical mediators of cellular communication that elicit
intracellular signaling by binding membrane-bound receptors. Here we demon-
strate the development and use of a sensitive real-time approach to quantify
secretion and receptor binding of native chemokines in live cells to better under-
stand their molecular interactions and function. CRISPR/Cas9 genome editing
was used to tag the chemokine CXCL12 with the nanoluciferase fragment HiBiT.
CXCL12 secretion was subsequently monitored and quantified by luminescence
output. Binding of tagged CXCL12 to either chemokine receptors or membrane
glycosaminoglycans could be monitored due to the steric constraints of nanoluci-
ferase complementation. Furthermore, binding of native CXCL12-HiBiT to Alexa-
Fluor488-tagged CXCR4 chemokine receptors could also be distinguished from
glycosaminoglycan binding and pharmacologically analyzed using BRET. These
live cell approaches combine the sensitivity of nanoluciferase with CRISPR/Cas9
genome editing to detect, quantify, and monitor binding of low levels of native
secreted proteins in real time.
INTRODUCTION
Secreted peptides and proteins are critical for cellular communication, with changes in expression, secre-
tion, and subsequent binding to their cellular targets mediating numerous (patho)-physiological cellular
responses. Chemokines are a family of small cytokines secreted by cells that bind and activate G pro-
tein-coupled receptors, resulting in immune cell migration; cell differentiation and development; and can-
cer metastasis (Hughes and Nibbs, 2018). The function of chemokines is controlled at the transcriptional as
well as the post-translational level. For example, numerous factors are known in vivo to induce the
expression and production of chemokines to recruit immune cells to inflamed tissue, whereas secreted che-
mokines bind membrane-bound proteoglycans to form chemotactic gradients that guide immune cell
migration (Proudfoot et al., 2017; Stone et al., 2017). Investigating and quantifying chemokine ligand secre-
tion from cells, as well as interactions with glycosaminoglycans (GAGs) found on proteoglycans and their
receptors, is therefore important to properly understand chemokine regulation and function.
CXCL12, also known as stromal derived factor, is a prototypical chemokine that binds CXCR4 to mediate
immune cell migration and cellular differentiation (Busillo and Benovic, 2007) and is a known biomarker for
a number of cancers (Samarendra et al., 2017). Like many secreted proteins, methods to quantify chemo-
kine expression rely on monitoring mRNA transcript levels or mass spectrometry and immunoassay assays
such as ELISA and western blotting to determine protein levels. However, these methods have limited
sensitivity for detecting poorly expressed proteins and, in the case of immunoassays, rely on the availability
of sensitive and selective antibodies (McDonough et al., 2015). Such approaches are also relatively low
throughput and lack the temporal fidelity required to investigate chemokine secretion in a real-time
manner. In addition, these methods only inform on the expression of the chemokine without imparting
knowledge of downstream signaling. Detailed pharmacological analysis of chemokine binding to their
cellular targets, i.e. chemokine receptors, proteoglycans or GAGs, is therefore commonly monitored
separately using approaches such as radio- or fluorescent ligand binding (Stoddart et al., 2016) and surface
plasmon resonance assays (Du et al., 2016). Such assays performed in live cell formats may struggle to
differentiate between the different binding sites, whereas those configured to look at specific interactions,
e.g. surface plasmon resonance, are performed with purified receptor and therefore occur in more artificialiScience 24, 102011, January 22, 2021 ª 2020 The Author(s).





Articleenvironments (Du et al., 2016). Furthermore, exogenous chemokine is used rather than chemokines
secreted from cells and expressed under endogenous promotion.
Fusion of a luciferase to a protein of interest has allowed a wide range of biological effects to be investi-
gated by bioluminescent technologies such as luciferase complementation and bioluminescence reso-
nance energy transfer (BRET) (Kaskova et al., 2016). Luciferase reporters have high signal-to-noise ratios,
therefore providing highly sensitive detection of low abundance proteins as well as excellent quantitation
over an extensive linear concentration range (Dixon et al., 2016; Hall et al., 2012). Previously, biolumines-
cence approaches using full-length or split Gaussia luciferase have been used to investigate CXCL12 bind-
ing to CXCR4 and to the atypical chemokine receptor ACKR3 both in vitro and in vivo (Luker et al., 2009,
2012; Luker and Luker, 2014). However, these studies used either purified luciferase-tagged CXCL12 or
cells secreting exogenous luciferase-tagged CXCL12 to monitor binding by luciferase complementation
or changes in luminescence, rather than endogenously expressed CXCL12. More recently, we have demon-
strated that ligand binding to CXCR4 and ACKR3 tagged with the nanoluciferase (NLuc) can be monitored
in live cells using CXCL12 labeled with AF647 and NanoBRET (White et al., 2020). It has been shown that a
split version of NLuc can be used to investigate peptide ligand binding to relaxin peptide family receptor 3
and 4 by NLuc complementation (Wang et al., 2019). However, in these studies the peptide used tomonitor
these interactions was exogenously derived.
Taking advantage of the brightness of NLuc (Hall et al., 2012), we and others have used CRISPR/Cas9-medi-
ated genome engineering to tag and then study genes and proteins expressed under endogenous promotion
using either full-length or split NLuc. This has allowed changes in gene expression or protein levels to be
measured and quantified (Lackner et al., 2015; Oh-Hashi et al., 2016; Schwinn et al., 2018), as well as ligand
binding and internalization (Boursier et al., 2020; White et al., 2020), protein-protein interactions (White
et al, 2017, 2020), post-translational modifications (Schwinn et al., 2018), and protein degradation (Riching
et al., 2018) to bemonitored in real-time live cell or lysed cell assays by NanoBRET or changes in luminescence
for NLuc complementation. Although these studies using CRISPR/Cas9 genome editing and luciferase tags
have principally investigated membrane bound and intracellular proteins, vascular endothelial growth factor
(VEGFA), a secreted growth factor, was previously taggedwith the small NLuc fragment (HiBiT) (Schwinn et al.,
2018) and expressionmeasured in a lytic cell assay at a single time point, indicating the potential for use of this
approach to monitor secreted chemokines. Biosensors capable of investigating both ligand secretion and
ligand binding of endogenously expressed proteins will be highly useful to understand cellular signaling. Us-
ing CRISPR/Cas9-mediated genome engineering, here we report a live cell assay that can be used to monitor
and quantify secretion of proteins expressed under endogenous promotion by luciferase complementation as
well as chemokine ligand binding by BRET in real-time and in live cells.
RESULTS AND DISCUSSION
Genome editing of CXCL12
CXCL12 is an essential chemokine secreted endogenously by many cells including the immortalized
HEK293 cell line that is commonly used to investigate receptor pharmacology. However, real-time live
cell assays to quantify endogenous CXCL12 levels are lacking. Here, we sought to develop such an assay
to monitor expression and secretion of endogenous CXCL12 from HEK293 cells and to do so we first used
CRISPR/Cas9 genome editing to append the small 11-amino acid fragments of NLuc, HiBiT, to the C-ter-
minus of CXCL12. The use of a small NLuc fragment rather than full-length NLuc simplifies and improves the
efficiency of the genome-editing process in cells. Indeed, we found homozygous HiBiT insertion into the
native CXCL12 locus (Figure S1), a low probability event in non-diploid HEK293 cells. The minimal size
also reduces the potential of the tag to perturb the function of CXCL12, with the placement of the HiBiT
tag on the C-terminus of CXCL12 based on the knowledge that the N-terminus is critical for CXCR4 acti-
vation (Crump et al., 1997) and previous fusion of Gaussia luciferase to CXCL12 in overexpression models
did not impede function (Luker et al., 2009). Indeed, as noted below the pharmacology of CXCL12-HiBiT
was similar to that seen previously for CXCL12-AF647 (White et al., 2020). This strategy using HiBiT rather
than full-length NLuc also limits the observable signal to secreted (extracellular) CXCL12 due to the cell
impermeant nature of the 18 kDa NLuc fragment (LgBiT) used for luciferase complementation.
Quantification of ligand secretion
In live HEK293 cells expressing genome-edited CXCL12-HiBiT incubated with LgBiT (30 nM), we observed a
gradual increase in luminescence (Figure 1A) over the course of 1 h, and increasing either cell number or2 iScience 24, 102011, January 22, 2021
Figure 1. Investigation of CXCL12-HiBiT secretion from genome-edited HEK293 cells
(A) Kinetic analysis of luminescence generated post-wash from HEK293 cells expressing genome-edited CXCL12-HiBiT
plated at 30,000 (white circles) or 60,000 (black circles) cells/well or wild-type HEK293 cells (squares) immediately
following LgBiT (30 nM) addition.
(B) Effect of cell number and post-wash incubation time on luminescence generated by addition of LgBiT (30 nM) to
HEK293 cells expressing genome-edited CXCL12-HiBiT.





Articleincubation time further augmented the increase in luminescence (Figures 1A and 1B), indicating contin-
uous CXCL12-HiBiT secretion. At longer time points, 2 and 4 h, we observed that the increase in lumines-
cence plateaued (Figure 1B). This is likely to be due to CXCL12-HiBiT secretion reaching equilibrium with
CXCL12-HiBiT sequestration and/or internalization following binding to glycosaminoglycans and endog-
enous CXCR4 expressed in HEK293 cells, respectively. Indeed, CXCR4 can internalize CXCL12 (Hoffmann
et al., 2012) and as noted below binding of CXCL12-HiBiT to glycosaminoglycans reduces the luminescent
output due to steric constraints. However, our initial data (Figure 1) report relative changes in expression
rather than provide absolute quantification of secreted protein. Such measures can be made using tradi-
tional immunoassays and are important for pharmacological evaluation of ligand function. To address
this, we sought to quantify expression through correlation with luminescent output.
Previous work has shown that complementation of the two NLuc fragments (HiBiT with LgBiT) is linear, with
luminescence extending over eight orders of magnitude (Schwinn et al., 2018). Here we took advantage ofiScience 24, 102011, January 22, 2021 3
Figure 2. Quantification of CXCL12-HiBiT expression in genome-edited HEK293 cells
Luminescence generated from purified LgBiT (100 nM) incubated with increasing concentrations of purified HiBiT-
Halotag (1 fM - 1 nM) was used to construct a linear standard curve to quantify CXCL12-HiBiT expression by linear
regression in wells seeded with either 30,000 (black bar) or 60,000 (white bar) genome-edited HEK293 cells. Points and




Articlethis relationship to quantify secreted CXCL12-HiBiT expression from our genome-edited live HEK293 cells
(Figure 2). At 2 h post-wash, when CXCL12 secretion had largely plateaued, we observed CXCL12-HiBiT
expression to be 0.41 G 0.10 pM (n = 6) and 0.79 G 0.14 pM (n = 6) in a 96 well plate seeded with
30,000 and 60,000 cells/well, respectively (Figure 2). Although the current data demonstrate absolute quan-
tification, this is of luciferase-tagged CXCL12 under endogenous promotion rather than endogenous
CXCL12, and CRISPR/Cas9 tagging of native proteins may alter expression (Khan et al., 2019; White
et al., 2020). Although no such effects were seen previously with insertion of small NLuc tags (White
et al., 2020), changes in expression relative to wild-type cells expressing untagged CXCL12 due to tagging
or genetic rewiring following prolonged passage may need to be considered. Commercial immunoassays
for CXCL12 detection regularly have a sensitivity of >1 pg/mL (0.1 nM) and normal working ranges of 10–
1,000 pg/mL. In contrast here, the sensitivity of the luminescent approach allowed detection of natively
expressed CXCL12-HiBiT that is at the absolute lower end of the sensitivity of immunoassays and was
approximately 1000-fold more sensitive than these approaches with measurable signal in the low fM range.
Moreover, we observed luminescence output that was linear over seven orders of magnitude, which
exceeds the typical dynamic range (2–3 orders of magnitude) seen with standard immunoassays. These re-
sults demonstrate the applicability of coupling genome editing with nanoluciferase tags to monitor
secreted protein levels in real time and in live cells. Importantly, these approaches overcome the low-
throughput non-live cell limitations of common techniques used to quantify protein expression, such as
ELISA and western blotting.
NanoBRET ligand binding
Exogenous CXCL12 tagged with full-length Gaussia luciferase have been used to investigate ligand bind-
ing at CXCR4 and ACKR3, with fusion of the luciferase having limited effects on CXCL12 function (Luker
et al., 2009). To ensure that CXCL12 tagged with HiBiT retained functionality and was not degraded
following secretion, we established a NanoBRET ligand binding configuration that should be widely appli-
cable to chemokines and other secreted proteins such as growth factors. Here, HEK293 cells expressing
genome-edited CXCL12-HiBiT were co-cultured with wild-type HEK293 cells or HEK293 cells transiently
transfected with SNAP/CXCR4. Binding of CXCL12-HiBiT to CXCR4 brings the donor luciferase (once it
has been complimented with cell impermeant purified LgBiT) on the ligand and a fluorescent reporter
on the receptor into close proximity, thereby increasing the BRET ratio that can be measured and inferred
as ligand binding. Compared with coincubation with wild-type HEK293 cells, we observed an increase in
BRET between CXCL12-HiBiT (complemented with purified LgBiT) and SNAP/CXCR4 labeled with cell im-
permeant Alexa Fluor 488 that was displaced in a concentration-dependent manner by the CXCR4 antag-
onist AMD3100 at the anticipated affinity (Figure 3, pIC50 = 6.97G 0.10, n = 5). Notably, the pharmacology4 iScience 24, 102011, January 22, 2021
Figure 3. Displacement of genome-edited CXCL12-HiBiT binding to SNAP/CXCR4 observed by NanoBRET
HEK293 cells expressing genome-edited CXCL12-HiBiT, co-cultured with wild-type HEK293 cells (white squares) or
HEK293 cells transiently transfected with SNAP/CXCR4 (black squares), were incubated in the absence or presence of
increasing concentrations of AMD3100 (1 pM–10 mM). CXCL12-HiBiT was complemented with purified LgBiT (30 nM) and
SNAP/CXCR4 labeled with cell impermeant Alexa Fluor 488. Bars represent basal BRET in the absence of AMD3100. Bars




Articleof CXCL12-HiBiT binding to SNAP/CXCR4 is similar to that observed previously using fluorescently tagged
CXCL12-AF647 (White et al., 2020), further demonstrating the functionality of CXCL12-HiBiT secreted from
these cells. Taken together, these data show that the genome-edited CXCL12-HiBiT is both secreted and
capable of binding to CXCR4 exogenously expressed in neighboring cells.
In addition to investigating binding using CXCL12 tagged with full-length luciferase, purified or secreted
CXCL12 tagged with split-Gaussia luciferase has been used to probe CXCR4 or ACKR3 tagged with the
corresponding Gaussia luciferase fragment in vitro and in vivo (Luker and Luker, 2014). More recent
studies have used split-NLuc complementation to investigate ligand binding at the relaxin-3 receptor
(Wang et al., 2019) or binding of a nanobody (VUN400-HiBiT) to CXCR4 tagged with split-NLuc frag-
ments (Soave et al., 2020). However, here we used NanoBRET rather than luciferase complementation
to investigate ligand binding. NanoBRET confers the advantage of reducing any confounding effects
due to the affinity of the luciferase complementation, particularly if investigating low-affinity ligand-
receptor interactions. Moreover, the high distance dependence of energy transfer in NanoBRET assays
distinguishes binding of CXCL12 at receptors from non-receptor binding such as at glycosaminoglycans
(GAGs). Indeed, as discussed below, this may be a useful consideration because interactions with GAGs
both regulate and add complexity to chemokine signaling (Proudfoot et al., 2017). Finally, traditional
NanoBRET binding assays where the receptor is tagged with NLuc requires suitable fluorescent ligands
that are not always readily available. Our approach achieves the benefits of NanoBRET ligand binding
without the need to generate complex fluorescent proteins/probes that may require recombinant
production.
Detection of interactions between chemokine and GAG
We have previously reported that knockout of CXCL12 from HEK293 cells decreases constitutive CXCR4
internalization, suggesting that sufficient endogenous CXCL12 is secreted to activate and internalize
CXCR4 (White et al., 2020). However, the apparent concentration of CXCL12-HiBiT that we observed is
approximately 300- to 1000-fold lower than the reported EC50 for CXCL12-mediated CXCR4 G protein
signaling (Levoye et al., 2009). It is known that ligand concentration within a plate-based cellular assay is
unlikely uniform (Gherbi et al., 2018) and that secreted chemokines can be concentrated/localized at the
cell surface by binding to GAGs, which increases the effective ligand concentration near the receptor
(Proudfoot et al., 2017). We have shown previously that when NLuc fragments are fused to proteins, steric
constraints can modulate the affinity of complementation (White et al., 2020), whereas binding of chemo-
kines to GAGs provides protection from proteolytic degradation as well as facilitates chemokineiScience 24, 102011, January 22, 2021 5
Figure 4. Monitoring CXCL12-glycosaminoglycan interactions by changes in luminescent output
(A) HEK293 cells expressing genome-edited CXCL12-HiBiT or wild-type HEK293 cells (downward triangles) were
incubated with increasing concentrations of purified LgBiT in the absence (black circles) or presence of surfen (10 mM,
white squares).
(B) Kinetic analysis of the effect of AMD3100 (1 mM, black square), surfen (10 mM, black circle), heparan sulfate (30 mg/mL,
downward triangle), AMD3100 (1 mM) plus heparan sulfate (30 mg/mL, white square), or surfen (10 mM) plus heparan sulfate
(30 mg/mL, white circle) on the baseline-corrected luminescence generated by HEK293 cells expressing genome-edited
CXCL12-HiBiT in the presence of 30 nM LgBiT.
(C) Purified HiBiT (1 nM) was incubated with increasing concentrations of purified LgBiT in the absence (black circles) or
presence of surfen (10 mM, white squares) or heparan sulfate (30 mg/mL, black triangles).
(D) Supernatants from HEK293 cells expressing genome-edited CXCL12-HiBiT or wild-type HEK293 cells (white circles)
were incubated with increasing concentrations of purified LgBiT in the absence (black circles) or presence of surfen
(10 mM, white squares) or heparan sulfate (30 mg/mL, black triangles).
(A, C, and D) points represent percentage of the maximum luminescence Gs.e.m. generated by complementation of
genome-edited CXCL12-HiBiT LgBiT in the vehicle control from four to six individual experiments performed in duplicate.




Articleoligomerization and clustering (Proudfoot et al., 2017). We therefore hypothesized that CXCL12 binding to
GAGs would impart such constraints on NLuc complementation and provide a mechanism to determine if
GAG-mediated accumulation was indeed occurring.
To test this, we first determined the affinity of NLuc complementation in our HEK293 cells expressing
genome-edited CXCL12-HiBiT. We found that in live cells the affinity of NLuc complementation
(CXCL12-HiBiT with LgBiT) was reduced (Kd = 11.6 G 1.48 nM, mean G s.e.m., Figure 4A) compared
with the affinity (700 pM) for purified NLuc fragments reported in the literature (Dixon et al., 2016) and
the affinity we observed using our methodologies (White et al., 2020), indicating that fusion of HiBiT to
CXCL12 modulated complementation. Next we used a small molecule glycosaminoglycan inhibitor
(Schuksz et al., 2008) surfen (10 mM) to pharmacologically disrupt CXCL12-GAG binding and observed a
small increase in the affinity of CXCL12-HiBiT-LgBiT complementation compared with the vehicle control
(Figure 4A; Kd = 5.93G 0.53 nM, meanG s.e.m., n = 6, p < 0.05), as well as an increase in the luminescence




Articleglycosaminoglycan, decreased luminescence and attenuated the surfen-mediated responses (Figure 4B,
p < 0.01, n = 5). In addition, we also observed that incubation of cells with AMD3100 (1 mM, Figure 4B)
increased luminescence output, indicating that CXCL12-HiBiT binds to both endogenous GAGs and
CXCR4 expressed in HEK293 cells. Supporting the ligand-induced change in complementation affinity be-
ing due to a specific interaction between CXCL12-HiBiT and GAGs, neither surfen (10 mM; Kd = 8.24G 0.87,
meanG s.e.m, n = 4) nor heparan sulfate (30 mg/mL; Kd = 7.16G 0.66, meanG s.e.m, n = 4) modulated the
affinity of purified HiBiT and purified LgBiT complementation compared with vehicle control (Figure 4C;
Kd = 7.15 G 0.66 nM, mean G s.e.m, n = 4), whereas we have previously reported that AMD3100 also
has no effect on this interaction (White et al., 2020). Therefore, the differences in complementation affinity
between HiBiT and LgBiT are, in part, due to conformational differences of CXCL12-HiBiT when bound to
GAGs and/or in oligomeric forms compared with when found in a free state.
Finally, in a subset of experiments we also investigated whether CXCL12-HiBiT was also bound to secreted
GAGs. In these studies, we observed that the affinity of NLuc complementation (CXCL12-HiBiT with LgBiT)
was also reduced compared with the affinity of purified NLuc fragments in supernatants collected from
genome-edited HEK293 cells (Figure 4D; Kd = 17.47 G 2.13 nM, mean G s.e.m., n = 6). We also observed
that surfen (10 mM; Kd = 7.46G 2.27 nM, meanG s.e.m., n = 4) increased the affinity of complementation as
well as luminescence output compared with the vehicle control but that AMD3100 (1 mM; Figure S2, n = 4)
had no effect. This demonstrates that CXCL12-HiBiT secreted from HEK293 cells can bind to secreted/
soluble GAGs and confirmed that no CXCR4, and therefore cells, were present in the supernatants.
Notably, heparan sulfate (30 mg/mL; Kd = 16.15 G 3.83 nM, mean G s.e.m., n = 4) did not modulate
CXCL12-HiBiT–LgBiT complementation affinity or luminescent output in CXCL12-HiBiT containing super-
natants compared with vehicle control. This suggests that most secreted CXCL12-HiBiT in the supernatants
is bound to GAGs, which prevents further interactions between CXCL12-HiBiT and exogenously applied
heparan sulfate. Comparison of the affinity of CXCL12-HiBiT-LgBiT complementation in live cells and su-
pernatants (Kd = 11.6 G 1.48 nM versus Kd = 17.47 G 2.13 nM) further supports this, as in live cells both
GAG bound and free CXCL12-HiBiT are likely present. Indeed, the decrease in luminescent output (Fig-
ure 4B) in the live cell assay caused by application of exogenous heparan sulfate is likely due to binding
of newly secreted or free CXCL12-HiBiT rather than binding to existing extracellular GAG bound
CXCL12-HiBiT.
Here we demonstrate that interactions between CXCL12 and GAG are occurring in cultures of HEK293 cells
and that by monitoring changes in NLuc complementation these interactions can be investigated in a live
cell assay. Although, as hypothesized, the results suggest a possible mechanism by which a cell may
achieve sufficient accumulation of endogenous CXCL12 at or near the membrane to activate CXCR4,
from the current study we are unable to differentiate CXCL12 binding to secreted versus membrane-bound
GAGs. Nevertheless, GAG binding also protects chemokines from proteolytic degradation and therefore
CXCL12-HiBiT binding to either secreted or membrane-bound GAGs would also facilitate extracellular
ligand accumulation. Interestingly, our observations also suggest that once secreted into the media and
free from the extracellular matrix, CXCL12-HiBiT is predominantly bound to GAGs. Within a cellular
signaling context, interactions between secreted chemokines and GAGs may limit degradation as well
as help maintain chemotactic gradients. Indeed, it is known that interactions between chemokine and
GAG are important for chemotaxis in vivo (Crijns et al., 2020) and that soluble chemokines that activate leu-
kocytes in the circulation prior to adhesion to the endothelium impair leukocyte adhesion and emigration
(Ley et al., 1993). Finally, it is noteworthy that although HEK293 cells are a common model cell line used to
study receptor function, the concurrent expression, membrane accumulation, and receptor activation of
endogenously secreted ligands from these cells are underappreciated and may confound the interpreta-
tion of results.Summary and future directions
In summary, the genome-editing approach described here allows the secretion and binding of endoge-
nous chemokines to GAGs or receptors to be readily inferred in live cell assays through changes in
luminescence and/or NanoBRET ligand-binding assays. These approaches monitor continuous peptide
secretion in real time and do not require the development of a selective and/or specific antibody. Impor-
tantly, binding specificity can be imparted using the NanoBRET modality that allows binding of secreted
ligand to receptors to be monitored while effectively eliminating observable ‘‘off-target’’ binding to




Articlehowever, thus far these interactions have primarily been explored in artificial/purified non-cell systems or in
cellular assays that poorly distinguish between multiple binding targets (Hamel et al., 2009), i.e. receptors
and GAGs. It is therefore envisioned that these in vitro approaches will be broadly applicable to investigate
secretion and binding of peptides and contribute to our understanding of chemokine-GAG binding and
chemokine-mediated signaling in cells.
Limitations of the study
All experiments in this study were performed in model HEK293 cells; therefore, the broad applicability of
the approach to other secreted peptides will depend on the ability to use CRISPR/Cas9 to edit cells of in-
terest. In general, fusion of HiBiT to a protein may alter protein stability or expression, and therefore, the
amount of HiBiT-tagged CXCL12 quantified may differ from the true levels of endogenous CXCL12 in
HEK293 cells. Finally, it was not possible by luciferase complementation to determine to which specific
types of proteoglycans/GAGs that CXCL12-HiBiT binds, but rather it was inferred that such interactions
are occurring. Such specific interactions may be able to be explored in the future using the NanoBRET-
binding approach described here.
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Figure S1: Genotyping of wildtype and genome-edited HEK293 cell lines, Related to Figure 1. 
PCR amplification using primers targeting the CXCL12 locus of genomic DNA extracted from wildtype 
(WT) HEK293 cells (lane 2) or HEK293 cells genome-edited to express CXCL12-HiBiT (lane 3). 
Wildtype PCR product at 314bp indicated by white arrow and black arrow indicates PCR product of 




Figure S2: Effect of CXCR4 inhibition on luminescent output from supernatants collected from 
HEK293 cells expressing genome-edited CXCL12-HiBiT, Related to Figure 4. Supernatants were 
incubated with purified LgBiT (3 nM, 30 nM or 300 nM) in the absence (white bars) or presence of 
AMD3100 (1 µM, black bars). Bars represent luminescence in relative light units (RLU) ± s.e.m. 
generated by complementation of genome-edited CXCL12-HiBiT and LgBiT from four individual 




AMD3100 was purchased from Selleckchem (USA). Heparan sulfate sodium salt from bovine kidney 
(heparan sulfate) and surfen hydrate (surfen) were from Sigma-Aldrich (United Kingdom). Furimazine, 
purified HiBiT (HiBiT-Halotag, control peptide) and purified LgBiT NLuc fragments were purchased from 
Promega (USA). Membrane impermeant SNAP-surface AF488 was purchased from New England 
Biolabs (United Kingdom). AMD3100 (10 mM) and heparan sulfate were dissolved in water. Surfen 
hydrate (10 mM) was dissolved in Dimethyl sulfoxide (DMSO). All further dilutions were performed in 
assay buffer containing 0.1% bovine serum albumin (BSA, Sigma-Aldrich, United Kingdom). 
Molecular Biology 
The CXCR4 cDNA sequences were provided through the ONCORNET consortium from Vrije 
Universiteit Amsterdam in pcDEF3 plasmids. pCDNA3.1 (+) neo expression constructs encoding 
SNAP/CXCR4 were generated as described previously (White et al., 2020), except that sig-SNAP 
(Gherbi et al., 2015) was ligated in frame using the restriction enzymes BamHI and XhoI in place of sig-
NLuc. 
 
CRISPR/Cas9 genome engineering 
Guide RNA construction was performed as described previously in the detailed protocol (Ran et al., 
2013). Briefly, guide sequences were designed using the CRISPR Design Tool (http://crispr.mit.edu/) 
to target the C-terminus of CXCL12 (ACTTGTTTAAAGCTTTCTCC) and ligated as complementary 
oligonucleotides 5’-AAACGGAGAAAGCTTTAAACAAGTC-3’ and 5’-
CACCGACTTGTTTAAAGCTTTCTCC-3’ into the pSpCas9(BB)-2A-Puro (PX459 V2) expression 
construct (from Feng Zhang, Addgene plasmid # 62988) linearized by the restriction enzyme BbsI 
(NEB). To introduce DNA encoding GSSG-HiBiT into the CXCL12 genomic locus, a donor repair 
template was designed using the human genome assembly (GRCh38/hg38) and UCSC genome 
browser (http://genome.ucsc.edu/). The repair template was synthesised as single stranded oligo DNA 
nucleotides (ssODN, Integrated DNA Technologies, Inc. (IDT)) and consisted of homology arms 
surrounding GSSG-HiBiT with the CXCL12 stop codon deleted and the PAM motif mutated by a silent 




GGGCAAA-3’. Positive clones were genotyped using Q5® High-Fidelity DNA Polymerase (New 
England Biolabs, UK) as per the manufacturer’s instructions and the oligonucleotides 5’-
CCTTCCTCCTGTGCAGCC-3’ and 5’-CAGGGTCTAAATGCTGGCAA-3’, which anneal outside the 
ssODN repair template. 
Cell culture 
HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma Aldrich) supplemented 
with 10% fetal calf serum at 37°C/5% CO2. Transfections were performed using FuGENE HD (Promega, 
USA) according to the manufacturer’s instructions. Cells were passaged or harvested using PBS 
(Sigma Aldrich) and trypsin (0.25% w/v in versene; Sigma Aldrich). CRISPR/Cas9 genome-engineering 
of HEK293T cells was performed as described previously (Ran et al., 2013; White et al., 2017). Briefly, 
HEK293T cells were seeded in 6 well plates at 300,000-400,000 cells per well and incubated for 24h at 
37°C/5% CO2. Cells were then transfected with px459 sgRNA/Cas9 expression constructs and the 
ssODN donor repair template. Cells were cultured for 24h then treated with puromycin (0.3 µg/ml, 
Sigma-Aldrich) for 3 days to select for transfected cells. Following selection, cells were single cell cloned 
and allowed to expand for 2-3 weeks. Following expansion single clones expressing CXCL12-HiBiT 
were screened for luminescence following the addition of furimazine (10 µM) and purified LgBiT (10 
nM) using a PHERAStar FS plate reader (BMG LabTech). 
 
CXCL12-HiBiT assays 
To investigate CXCL12-HiBiT secretion, wildtype or HEK293 cells expressing genome-edited CXCL12-
HiBiT were seeded into poly-D-lysine coated white flat bottom 96 well plates at 30,000 or 60,000 
cells/well and incubated for 24h at 37°C/5%CO2. On the day of the assay, cells were washed and 
incubated with 50 µL/well pre-warmed 1x HEPES Buffered Salt Solution (1xHBSS; 25mM HEPES, 
10mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2mM sodium pyruvate, 1.3mM CaCl2, 1.8g/L 
glucose; pH 7.2) supplemented with 0.1% BSA for 1, 2 or 4 hours or immediately incubated with purified 
LgBiT (30 nM) and furimazine (10 µM). Total luminescence was then measured on a PHERAStar FS 
plate reader. Analysis of the effect of time and cell number on CXCL12-HiBiT expression was performed 
at 20 minutes post LgBiT addition. In assays to investigate the effect of glycosaminoglycan or CXCR4 
modulation on the levels of observable CXCL12-HiBiT, cells were washed with HBSS then incubated 
with HBSS supplemented with 0.1% BSA and 30 nM purified LgBiT for 2h 37°C. Furimazine (10 µM) 
was added to cells and allowed to equilibrate for 5 minutes before total luminescence was measured 
on a PHERAStar FS plate reader and 5 basal reads were taken. At time = 0, HBSS, AMD3100 (1 µM), 
surfen (10 µM), heparan sulfate (30 µg/mL), AMD3100 (1 µM) plus heparan sulfate (30 µg/mL) or surfen 
(10 µM) plus heparan sulfate (30 ug/mL) were added to the wells and total luminescence was measured. 
Baseline corrected luminescence was calculated by subtracting vehicle (HBSS)-treated luminescence 
from the ligand-treated luminescence.  
 
Quantification of tagged protein by luciferase activity 
To quantify CXCL12-HiBiT expression, wildtype HEK293 cells or HEK293 cells expressing genome-
edited CXCL12-HiBiT were seeded into poly-D-lysine coated white flat bottom 96 well plates at 30,000 
or 60,000 cells/well and incubated for 24h at 37°C/5% CO2. On the day of the assay, genome-edited 
CXCL12-HiBiT HEK293 cells were washed and incubated with pre-warmed HBSS for 2h at 37°C. A log 
HiBiT control protein (HiBiT-HaloTag, Promega, USA) standard curve (1 fM - 1 nM) was constructed in 
parallel by diluting the purified HiBiT control protein in HBSS supplemented with 0.1% BSA and adding 
to wells containing wildtype HEK293 cells. Purified LgBiT (100 nM) was then added to each well and 
cells incubated for a further 5 minutes before 10 μM furimazine was added and total light emissions 
were measured on a PHERAStar FS plate reader. Total assay volume was 50 µL/well. 
 
CXCL12-HiBiT NanoBRET ligand binding 
For CXCL12-HiBiT NanoBRET competition ligand binding assays, wildtype HEK293 cells were seeded 
in 6 well plates at 300,000 cells per well and incubated for 24h at 37°C/5% CO2. Cells were then 
transfected with 500 ng/well pcDNA3.1 (neo) plasmid encoding SNAP/CXCR4 and incubated for a 
further 24h. Transfected or un-transfected HEK293 cells were then seeded with HEK293 cells 
expressing genome-edited CXCL12-HiBiT into poly-D-lysine coated white flat bottom 96 well plates, at 
20,000 cells/well of each cell line and incubated for 24h at 37°C/5% CO2. On the day of the assay, cells 
were incubated with 0.25 µM membrane impermeant SNAP-surface AF488 for 1h at 37°C/5% CO2 
prepared in 100 µL/well serum-free DMEM. After incubation, cells were washed 3 times with pre-
warmed HBSS and incubated with purified 30 nM purified LgBiT in the absence or presence of 
AMD3100 (1 pM – 10 µM) for 2h at 37°C with a total assay volume of 50 µL/well. Following ligand 
incubation, 10 μM furimazine was added and plates equilibrated for 5 mins at room temperature. 
Sequential filtered light emissions were recorded using a PHERAStar FS plate reader using 475 nm 
(30 nm bandpass) and 535 nm (30 nm bandpass) filters. BRET ratios were calculated by dividing the 
535 nm emission (acceptor) by the 475 nm emission (donor). 
 
Determination of CXCL12-HiBiT-LgBiT affinity 
To investigate the affinity of CXCL12-HiBiT-LgBiT complementation, HEK293 cells expressing genome-
edited CXCL12-HiBiT or wildtype HEK293 cells were seeded into poly-D-lysine coated white flat bottom 
96 well plates at 30,000 cells/well and incubated for 24h at 37°C/5% CO2. On the day of the assay, cells 
were washed and incubated with HBSS supplemented with 0.1% BSA for 2hrs at 37°C. Cells expressing 
genome-edited CXCL12-HiBiT were then incubated with increasing concentrations of purified LgBiT for 
30 minutes at 37°C in the absence or presence of surfen (10 µM). In parallel, non-specific luminescence 
was determined by adding purified LgBiT to wells containing wildtype cells only. Total assay volume 
was 50 µL/well. Following incubation, furimazine (10 µM) was added, plates incubated for 5 minutes, 
and total light emissions measured using a PHERAStar FS plate reader. In a subset of experiments on 
the day of assay cells were washed and incubated with 50 uL/well HBSS supplemented with 0.1% BSA 
for 2hrs at 37°C before 30 uL of supernatant was collected and transferred to a new white flat bottom 
96 well plate and a plate back added. Supernatants were then incubated with increasing concentrations 
of purified LgBiT for 30 minutes at 37°C in the absence or presence of surfen (10 µM), or Heparan 
sulfate (30 µg/ml). Before total light emissions were measured as described above. Total assay volume 
was 50 µL/well and non-specific luminescence was determined by adding purified LgBiT to wells 
containing supernatant from wildtype cells only. The effect of surfen or heparan sulfate on the affinity 
complementation of purified HiBiT and LgBiT was determined as described previously using a 50 
µL/well total assay volume (White et al., 2020). 
 
Data presentation and statistical analysis  
BRET ratios were calculated by dividing the acceptor emission by the donor emission. Calculation of 
baseline corrected BRET ratios or luminescence values are described in the methods for each assay 
configuration.  
Prism 7 software was used to analyse ligand-binding curves. For CXCL12-HiBiT – purified LgBiT 
saturation complementation assays, total and non-specific saturation binding curves were 
simultaneously fitted using the following equation: 
𝐵𝑅𝐸𝑇	𝑅𝑎𝑡𝑖𝑜 =
𝐵𝑚𝑎𝑥 ∗ [𝐵]
[𝐵] + 𝐾𝐷 + (
(𝑀 ∗ [𝐵]) + 𝐶) 
where Bmax is the maximal response, [B] is the concentration of LgBiT in nM, KD is the equilibrium 
dissociation constant in nM, M is the slope of the non-specific binding component and C is the intercept 
with the Y-axis. Luminescence generated by LgBiT [B] incubated on wildtype cells was used as non-
specific binding.  
Inhibition concentration response-data were fitted using the following equation: 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
𝐵𝑚𝑎𝑥 − 𝐵
( [𝐿]𝐼𝐶50) + 1
+ 𝐵 
where Bmax is the maximum response of the probe, B is the non-specific binding or response, with 
both Bmax and B defined from the plateaus of the curve. [L] is the concentration of the competing 
ligand, IC50 is the concentration of the competition ligand required to inhibit 50% of the maximum 
response. pIC50 values were calculated as -log IC50. 
Quantification of HiBiT-CXCL12 expression was interpolated by Prism from linear regression of a log-
log standard curve fitted with the following equation: 
𝑌 = 𝐴 + 𝐵[𝑋] 
where [X] is the concentration of HiBiT, Y is the luminescence output, A is the y-intercept and B is the 
slope of the line. Complementation of HiBiT-LgBiT has been reported to produce a linear correlation 
extending over 8 orders of magnitude (Schwinn et al., 2018). Here we observed a linear correlation of 
R2 = 0.99, with a slope of 0.85 ± 0.04 (n=6). Statistical analysis was performed using Prism 7 software 
(GraphPad, San Diego, USA) using one or two-way ANOVA with appropriate multiple comparisons 
tests where required. Specific statistical tests used are indicated in the figure legends and were 
performed on the mean data of individual experiments (n) also indicated in the figure legends. A p-value 
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